The impact of COVID-19 on patients with asthma
EntityUAM. Departamento de Medicina
PublisherEuropean Respiratory Society
10.1183/13993003.03142-2020European Respiratory Journal 57.3 (2021): 2003142
Funded byGrant COVID-19 UAH 2019/00003/016/001/005 from the University of Alcalá (Spain)
Editor's Versionhttp://doi.org/ 10.1183/13993003.03142-2020
SubjectsCOVID-19; asthma; Medicina
Rights© ERS 2021
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
Background: An association between the severity of coronavirus disease 2019 (COVID-19) and the presence of certain chronic conditions has been suggested. However, unlike influenza and other viruses, the disease burden of COVID-19 in patients with asthma has been less evident. Objective: To understand the impact of COVID-19 in patients with asthma. Methods: Using big-data analytics and artificial intelligence through the SAVANA Manager clinical platform, we analysed clinical data from patients with asthma from January 1 to May 10, 2020. Results: Out of 71182 patients with asthma, 1006 (1.41%) suffered from COVID-19. Compared to asthmatic individuals without COVID-19, patients with asthma and COVID-19 were significantly older (55 versus 42 years), predominantly female (66% versus 59%), smoked more frequently and had higher prevalence of hypertension, dyslipidaemias, diabetes and obesity. Allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19 (p<0.001). In addition, higher prevalence of these comorbidities was observed in patients with COVID-19 who required hospital admission. The use of inhaled corticosteroids (ICS) was lower in patients who required hospitalisation due to COVID-19, as compared to non-hospitalised patients (48.3% versus 61.5%; OR 0.58, 95% CI 0.44-0.77). Although patients treated with biologics (n=865; 1.21%) showed increased severity and more comorbidities at the ear, nose and throat level, COVID-19-related hospitalisations in these patients were relatively low (0.23%). Conclusion: Patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection
Google Scholar:Izquierdo, José Luis - Almonacid, Carlos - González, Yolanda - Del Rio-Bermudez, Carlos - Ancochea Bermúdez, Julio - Cárdenas, Remedios - Lumbreras, Sara - Soriano, Joan B.
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Hospital epidemics tracker (hepitracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers Soriano, Joan B.; Fernández, Esteve; de Astorza, Álvaro; Pérez de Llano, Luis A.; Fernández-Villar, Alberto; Carnicer-Pont, Dolors; Alcázar-Navarrete, Bernardino; García, Arturo; Morales, Aurelio; Lobo, María; Maroto, Marcos; Ferreras, Eloy; Soriano, Cecilia; Del Rio-Bermudez, Carlos; Vega-Piris, Lorena; Basagaña, Xavier; Muncunill, Josep; Cosio, Borja G.; Lumbreras, Sara; Catalina, Carlos; Alzaga, José María; Gómez Quilón, David; Valdivia, Carlos Alberto; de Lara, Celia; Ancochea Bermúdez, Julio